1. Home
  2. ATHE vs CDT Comparison

ATHE vs CDT Comparison

Compare ATHE & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHE
  • CDT
  • Stock Information
  • Founded
  • ATHE 1997
  • CDT 2019
  • Country
  • ATHE Australia
  • CDT United States
  • Employees
  • ATHE N/A
  • CDT 7
  • Industry
  • ATHE Biotechnology: Pharmaceutical Preparations
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATHE Health Care
  • CDT Health Care
  • Exchange
  • ATHE Nasdaq
  • CDT Nasdaq
  • Market Cap
  • ATHE 10.1M
  • CDT 9.0M
  • IPO Year
  • ATHE N/A
  • CDT N/A
  • Fundamental
  • Price
  • ATHE $2.20
  • CDT $0.07
  • Analyst Decision
  • ATHE Strong Buy
  • CDT
  • Analyst Count
  • ATHE 2
  • CDT 0
  • Target Price
  • ATHE $6.00
  • CDT N/A
  • AVG Volume (30 Days)
  • ATHE 121.1K
  • CDT 16.2M
  • Earning Date
  • ATHE 02-15-2025
  • CDT 02-14-2025
  • Dividend Yield
  • ATHE N/A
  • CDT N/A
  • EPS Growth
  • ATHE N/A
  • CDT N/A
  • EPS
  • ATHE N/A
  • CDT N/A
  • Revenue
  • ATHE $2,681,669.00
  • CDT N/A
  • Revenue This Year
  • ATHE N/A
  • CDT N/A
  • Revenue Next Year
  • ATHE N/A
  • CDT N/A
  • P/E Ratio
  • ATHE N/A
  • CDT N/A
  • Revenue Growth
  • ATHE 2.63
  • CDT N/A
  • 52 Week Low
  • ATHE $1.00
  • CDT $0.06
  • 52 Week High
  • ATHE $3.19
  • CDT $5.44
  • Technical
  • Relative Strength Index (RSI)
  • ATHE 64.85
  • CDT 40.15
  • Support Level
  • ATHE $2.04
  • CDT $0.08
  • Resistance Level
  • ATHE $2.45
  • CDT $0.09
  • Average True Range (ATR)
  • ATHE 0.23
  • CDT 0.01
  • MACD
  • ATHE -0.00
  • CDT -0.00
  • Stochastic Oscillator
  • ATHE 71.15
  • CDT 27.18

About ATHE Alterity Therapeutics Limited

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: